Here are the 10-Q quarterly reports from Cyanotech Corp (CYAN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CYAN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYAN filings page.
Cyanotech Corporation (CYAN) filed its quarterly report for the period ended September 30, 2025. Net sales rose to $6.976 million from $5.845 million, driven by stronger packaged and bulk astaxanthin and spirulina demand. Gross profit improved to $2.393 million with margin at 34.3% versus 25.3% a year ago as higher production volumes lowered unit costs and select price increases aided mix.
Operating expenses fell to $2.203 million, producing operating income of $190,000 (prior year loss of $975,000). After interest expense of $189,000, net income was $1,000, or $0.00 per share. For the six months, net sales were $12.797 million and net loss was $925,000.
Liquidity remains tight: cash was $649,000 and working capital $39,000. Debt included $370,000 on the 2023 bank term loan (maturing March 31, 2026), $2.809 million on the 2012 loan (amortizing to August 2032), and a related-party revolver with $4.200 million outstanding (capacity $4.600 million, expiring April 12, 2027). The company notes substantial doubt about continuing as a going concern, citing prior covenant noncompliance (waived) and a bank freeze on further line advances. As of November 1, 2025, common shares outstanding were 7,392,243.